Isomerase Therapeutics Ltd (Cambridge, UK), is delighted to announce that it has signed a lease for a new 3,495 square foot facility at Solopark, Cambridge, UK. This is in addition to its existing facility in Chesterford Research Park and will enable Isomerase to significantly expand its biomanufacturing capability.
VP of Bioprocess, Neil Triggs elaborated “Following leasing of the new space, we are now initially fitting this out with a kilo-lab scaled biomanufacturing capability, but have the space to further expand this in the future. This will enable fermentation and downstream processing of a variety of biomanufactured products, including enzymes, natural products, peptides and sustainable products.”
Matt Gregory, the CEO of Isomerase added “The new facility will offer us the ability to generate material for partners from grams to kilos, enabling us to take bioprocesses for partners all the way from concept to prototype.”
Our team is uniquely placed to assist partners with all aspects of microbial product and process discovery and development, including leading-edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, Isomerase manages other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping and scaled manufacture.
We offer these capabilities underpinned by a portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful product discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
For more information please contact Isomerase via our contact page.